Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.

Heideman DAM, Xu L, Hesselink AT, Doorn S, Ejegod DM, Pedersen H, Quint WGV, Bonde J, Arbyn M.

J Clin Virol. 2019 Oct 12;121:104201. doi: 10.1016/j.jcv.2019.104201. [Epub ahead of print]

2.

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.

Vink FJ, Meijer CJLM, Clifford GM, Poljak M, Oštrbenk A, Petry KU, Rothe B, Bonde J, Pedersen H, de Sanjosé S, Torres M, Del Pino M, Quint WGV, Cuschieri K, Boada EA, van Trommel NE, Lissenberg-Witte BI, Floore AN, Hesselink AT, Steenbergen RDM, Bleeker MCG, Heideman DAM.

Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614. [Epub ahead of print]

PMID:
31390052
3.

Selection of women at risk for cervical cancer in an HIV-infected South African population.

Van Zummeren M, Kremer WW, Van Aardt MC, Breytenbach E, Richter KL, Rozendaal L, Witte BI, De Strooper LMA, Hesselink AT, Heideman DAM, Snijders PJF, Steenbergen RDM, Dreyer G, Meijer CJLM.

AIDS. 2017 Sep 10;31(14):1945-1953. doi: 10.1097/QAD.0000000000001583.

PMID:
28692545
4.

Higher HPV16 and HPV18 Penile Viral Loads Are Associated With Decreased Human Papillomavirus Clearance in Uncircumcised Kenyan Men.

Senkomago V, Backes DM, Hudgens MG, Poole C, Meshnick SR, Agot K, Moses S, Snijders PJ, Meijer CJ, Hesselink AT, Schlecht NF, Bailey RC, Smith JS.

Sex Transm Dis. 2016 Sep;43(9):572-8. doi: 10.1097/OLQ.0000000000000500.

5.

Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM.

Gynecol Oncol. 2016 May;141(2):341-347. doi: 10.1016/j.ygyno.2016.02.012. Epub 2016 Mar 3.

6.

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.

Hesselink AT, Sahli R, Berkhof J, Snijders PJ, van der Salm ML, Agard D, Bleeker MC, Heideman DA.

J Clin Virol. 2016 Mar;76:36-9. doi: 10.1016/j.jcv.2016.01.009. Epub 2016 Jan 15.

7.

Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya.

De Vuyst H, Franceschi S, Plummer M, Mugo NR, Sakr SR, Meijer CJ, Heideman DA, Tenet V, Snijders PJ, Hesselink AT, Chung MH.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):311-8. doi: 10.1097/QAI.0000000000000744.

PMID:
26473640
8.

Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.

Verhoef VM, van Kemenade FJ, Rozendaal L, Heideman DA, Bosgraaf RP, Hesselink AT, Melchers WJ, Massuger LF, Bekkers RL, Steenbergen RD, Berkhof J, Snijders PJ, Meijer CJ.

Gynecol Oncol. 2015 Apr;137(1):55-9. doi: 10.1016/j.ygyno.2015.01.550. Epub 2015 Feb 8.

PMID:
25667975
9.

CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer.

De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, Snijders PJ, Heideman DA, Meijer CJ.

J Clin Pathol. 2014 Dec;67(12):1067-71. doi: 10.1136/jclinpath-2014-202616. Epub 2014 Oct 3.

PMID:
25281766
10.

Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions.

De Strooper LM, Meijer CJ, Berkhof J, Hesselink AT, Snijders PJ, Steenbergen RD, Heideman DA.

Cancer Prev Res (Phila). 2014 Dec;7(12):1251-7. doi: 10.1158/1940-6207.CAPR-14-0237. Epub 2014 Oct 3.

11.

Acquisition and persistence of human papillomavirus 16 (HPV-16) and HPV-18 among men with high-HPV viral load infections in a circumcision trial in Kisumu, Kenya.

Senkomago V, Backes DM, Hudgens MG, Poole C, Agot K, Moses S, Snijders PJ, Meijer CJ, Hesselink AT, Schlecht NF, Bailey RC, Smith JS.

J Infect Dis. 2015 Mar 1;211(5):811-20. doi: 10.1093/infdis/jiu535. Epub 2014 Sep 26.

12.

Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer.

Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, Bekkers RL, Massuger LF, Steenbergen RD, Snijders PJ, Berkhof J, Meijer CJ.

Gynecol Oncol. 2014 Oct;135(1):58-63. doi: 10.1016/j.ygyno.2014.08.003. Epub 2014 Aug 8.

PMID:
25111387
13.

Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women.

De Strooper LM, Hesselink AT, Berkhof J, Meijer CJ, Snijders PJ, Steenbergen RD, Heideman DA.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1933-7. doi: 10.1158/1055-9965.EPI-14-0347. Epub 2014 Jun 24.

14.

Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.

Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, Bekkers RL, Steenbergen RD, Massuger LF, Melchers WJ, Bulten J, Overbeek LI, Berkhof J, Snijders PJ, Meijer CJ.

Lancet Oncol. 2014 Mar;15(3):315-22. doi: 10.1016/S1470-2045(14)70019-1. Epub 2014 Feb 13.

PMID:
24529697
15.

Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy.

Hesselink AT, Heideman DA, Steenbergen RD, Gök M, van Kemenade FJ, Wilting SM, Berkhof J, Meijer CJ, Snijders PJ.

Int J Cancer. 2014 Aug 15;135(4):880-6. doi: 10.1002/ijc.28723. Epub 2014 Jan 28.

16.

Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.

Hesselink AT, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, Bleeker MG, Heideman DA.

J Clin Microbiol. 2014 Mar;52(3):890-6. doi: 10.1128/JCM.03195-13. Epub 2014 Jan 3.

17.

Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas.

Rietbergen MM, Snijders PJ, Beekzada D, Braakhuis BJ, Brink A, Heideman DA, Hesselink AT, Witte BI, Bloemena E, Baatenburg-De Jong RJ, Leemans CR, Brakenhoff RH.

Int J Cancer. 2014 May 15;134(10):2366-72. doi: 10.1002/ijc.28580. Epub 2013 Nov 19.

18.

The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.

Heideman DA, Hesselink AT, van Kemenade FJ, Iftner T, Berkhof J, Topal F, Agard D, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2013 Nov;51(11):3653-7. doi: 10.1128/JCM.01517-13. Epub 2013 Aug 28.

19.

A second generation cervico-vaginal lavage device shows similar performance as its preceding version with respect to DNA yield and HPV DNA results.

Verhoef VM, Dijkstra MG, Bosgraaf RP, Hesselink AT, Melchers WJ, Bekkers RL, Berkhof J, van Kemenade FJ.

BMC Womens Health. 2013 May 2;13:21. doi: 10.1186/1472-6874-13-21.

20.

Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.

Hesselink AT, Meijer CJ, Poljak M, Berkhof J, van Kemenade FJ, van der Salm ML, Bogaarts M, Snijders PJ, Heideman DA.

J Clin Microbiol. 2013 Jul;51(7):2409-10. doi: 10.1128/JCM.00633-13. Epub 2013 May 1.

21.

CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease.

Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB, van der Zee AG, Snijders PJ, Steenbergen RD.

Int J Cancer. 2013 Sep 15;133(6):1293-9. doi: 10.1002/ijc.28138. Epub 2013 Apr 4.

22.

Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape.

Snellenberg S, De Strooper LM, Hesselink AT, Meijer CJ, Snijders PJ, Heideman DA, Steenbergen RD.

BMC Cancer. 2012 Nov 23;12:551. doi: 10.1186/1471-2407-12-551.

23.

Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.

Rietbergen MM, Leemans CR, Bloemena E, Heideman DA, Braakhuis BJ, Hesselink AT, Witte BI, Baatenburg de Jong RJ, Meijer CJ, Snijders PJ, Brakenhoff RH.

Int J Cancer. 2013 Apr 1;132(7):1565-71. doi: 10.1002/ijc.27821. Epub 2012 Nov 23.

24.

Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN.

Dijkstra MG, Heideman DA, van Kemenade FJ, Hogewoning KJ, Hesselink AT, Verkuijten MC, van Baal WM, Boer GM, Snijders PJ, Meijer CJ.

J Clin Virol. 2012 Jun;54(2):147-51. doi: 10.1016/j.jcv.2012.02.022. Epub 2012 Mar 23.

PMID:
22445557
25.

Clinical validation of the cobas 4800 HPV test for cervical screening purposes.

Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, Verkuijten M, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2011 Nov;49(11):3983-5. doi: 10.1128/JCM.05552-11. Epub 2011 Aug 31.

26.

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening.

Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ.

Int J Cancer. 2012 Feb 1;130(3):602-10. doi: 10.1002/ijc.26056. Epub 2011 May 5.

27.

Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women.

Hesselink AT, Heideman DA, Steenbergen RD, Coupé VM, Overmeer RM, Rijkaart D, Berkhof J, Meijer CJ, Snijders PJ.

Clin Cancer Res. 2011 Apr 15;17(8):2459-65. doi: 10.1158/1078-0432.CCR-10-2548. Epub 2011 Mar 9.

28.

Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women.

Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, Wilting SM, Heideman DA, Verheijen RH, Zaal A, van Baal WM, Berkhof J, Snijders PJ, Steenbergen RD.

Int J Cancer. 2011 Nov 1;129(9):2218-25. doi: 10.1002/ijc.25890. Epub 2011 Mar 11.

29.

Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Rijkaart DC, Coupe VM, van Kemenade FJ, Heideman DA, Hesselink AT, Verweij W, Rozendaal L, Verheijen RH, Snijders PJ, Berkhof J, Meijer CJ.

Br J Cancer. 2010 Sep 28;103(7):939-46. doi: 10.1038/sj.bjc.6605869. Epub 2010 Aug 31.

30.

Validation of high-risk HPV tests for primary cervical screening.

Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ.

J Clin Virol. 2009 Nov;46 Suppl 3:S1-4. doi: 10.1016/S1386-6532(09)00540-X.

PMID:
20129067
31.

Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.

Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2010 Mar;48(3):797-801. doi: 10.1128/JCM.01743-09. Epub 2009 Dec 30.

32.

High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer.

Hesselink AT, Berkhof J, Heideman DA, Bulkmans NW, van Tellingen JE, Meijer CJ, Snijders PJ.

Int J Cancer. 2009 Jan 15;124(2):381-6. doi: 10.1002/ijc.23940.

33.

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.

Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ.

Int J Cancer. 2009 Feb 1;124(3):516-20. doi: 10.1002/ijc.24010.

34.

Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia.

Hesselink AT, van Ham MA, Heideman DA, Groothuismink ZM, Rozendaal L, Berkhof J, van Kemenade FJ, Massuger LA, Melchers WJ, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2008 Oct;46(10):3215-21. doi: 10.1128/JCM.00476-08. Epub 2008 Aug 6.

35.

Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation.

van Houdt IS, Muris JJ, Hesselink AT, Kramer D, Cillessen SA, Moesbergen LM, Vos W, Hooijberg E, Meijer CJ, Kummer JA, Oudejans JJ.

Histopathology. 2007 Dec;51(6):778-84.

PMID:
18042067
36.

A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.

Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH.

Int J Cancer. 2007 Dec 1;121(11):2465-72.

37.

Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2006 Oct;44(10):3680-5.

38.

High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush.

Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade F, Fransen Daalmeijer N, Hesselink AT, Berkhof J, Snijders PJ.

J Clin Microbiol. 2006 Jul;44(7):2518-23.

39.

Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology.

Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, Meijer CJ.

Int J Cancer. 2006 Sep 1;119(5):1102-7.

40.

Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens.

Hesselink AT, van den Brule AJ, Groothuismink ZM, Molano M, Berkhof J, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2005 Sep;43(9):4868-71.

41.

Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads.

Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, van Diemen PM, van den Brule AJ, Snijders PJ, Meijer CJ.

Clin Infect Dis. 2005 Sep 1;41(5):612-20. Epub 2005 Jul 25.

PMID:
16080082
42.

Dimerization of glycoprotein E(rns) of classical swine fever virus is not essential for viral replication and infection.

van Gennip HG, Hesselink AT, Moormann RJ, Hulst MM.

Arch Virol. 2005 Nov;150(11):2271-86. Epub 2005 Jun 28.

PMID:
15986175
43.

HPV-associated flat penile lesions in men of a non-STD hospital population: less frequent and smaller in size than in male sexual partners of women with CIN.

Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Berkhof J, Hesselink AT, Lettink M, Starink TM, Stoof TJ, Snijders PJ, Meijer CJ.

Int J Cancer. 2005 Jan 1;113(1):36-41.

44.

Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples.

Hesselink AT, van den Brule AJ, Brink AA, Berkhof J, van Kemenade FJ, Verheijen RH, Snijders PJ.

Cancer. 2004 Feb 25;102(1):11-8.

Supplemental Content

Loading ...
Support Center